Cognitive Impairment: Assessment With Brain Magnetic Resonance Imaging and Proton Magnetic Resonance Spectroscopy
J Clin Psychiatry 2003;64(3):235-242
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: In vivo proton magnetic resonance
spectroscopy is a safe and noninvasive tool that can be used to
study aspects of brain chemistry and metabolism. This study was
designed to evaluate its role in routine application to reveal
the diagnostic reasons for cognitive impairment.
Method: 37 Alzheimer's disease patients
(NINCDS-ADRDA criteria), 31 patients with subcortical ischemic
vascular dementia (Chui et al. criteria), and 13 subjects with
subjective cognitive impairment (DSM-IV criteria) were included
in this retrospective study. Magnetic resonance images were used
for atrophy rating; additionally, proton magnetic resonance
spectroscopy was performed.
Results: Significantly reduced N-acetylaspartate
levels (p < .05) were found in both patients with Alzheimer's
disease and patients with subcortical ischemic vascular dementia
compared to the group with subjective memory complaints. The
ratios of N-acetylaspartate/creatine and
N-acetylaspartate/myo-inositol were significantly lower in
Alzheimer's disease patients compared to patients with vascular
dementia (p = .012) or patients with subjective memory impairment
(p = .002). N-acetylaspartate/creatine and
N-acetylaspartate/myo-inositol ratios were positively correlated
to the degree of cerebral atrophy. Disoriented patients displayed
a low N-acetylaspartate/creatine ratio. In contrast, we were not
able to relate concurrent psychotic or behavioral symptoms to any
Conclusion: This study indicates that proton
magnetic resonance spectroscopy parameters could provide
additional information in differentiating between Alzheimer's
disease, subcortical ischemic vascular dementia, and subjective
cognitive impairment. Therefore, this method can contribute to
the routine diagnosis of dementia. Psychiatric and behavioral
symptoms associated with dementia or due to a major psychiatric
disorder cannot be related to changes in the measured proton
magnetic resonance spectroscopy parameters.